BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27567286)

  • 1. RANKL Signaling and ErbB Receptors in Breast Carcinogenesis.
    Zoi I; Karamouzis MV; Adamopoulos C; Papavassiliou AG
    Trends Mol Med; 2016 Oct; 22(10):839-850. PubMed ID: 27567286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
    Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
    Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.
    Sirinian C; Papanastasiou AD; Schizas M; Spella M; Stathopoulos GT; Repanti M; Zarkadis IK; King TA; Kalofonos HP
    Oncogene; 2018 Sep; 37(37):5101-5114. PubMed ID: 29844572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
    Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
    Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
    Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain.
    Wang K; Hackney JR; Siegal GP; Wei S
    Clin Breast Cancer; 2020 Oct; 20(5):e569-e575. PubMed ID: 32381383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
    Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
    Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.
    Boopalan T; Arumugam A; Parada J; Saltzstein E; Lakshmanaswamy R
    Cancer Sci; 2015 Jan; 106(1):25-33. PubMed ID: 25412610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progestogens and risk of breast cancer: a link between bone and breast?
    González Ricarte M; de Castro Pérez A; Tarín JJ; Cano A
    Gynecol Endocrinol; 2016; 32(1):6-8. PubMed ID: 26299383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
    Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bone metastasis and RANKL].
    Nakashima T
    Clin Calcium; 2014 Aug; 24(8):1201-8. PubMed ID: 25065872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Roadmap of RANKL/RANK Pathway in Cancer.
    Casimiro S; Vilhais G; Gomes I; Costa L
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ErbB4 in breast cancer.
    Sundvall M; Iljin K; Kilpinen S; Sara H; Kallioniemi OP; Elenius K
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):259-68. PubMed ID: 18454307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells.
    Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
    Biochem Biophys Res Commun; 2011 May; 408(3):411-6. PubMed ID: 21514280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.
    Schramek D; Sigl V; Penninger JM
    Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.